T-bet, GATA-3, and Foxp3 expression and th1/th2 cytokine production in the clinical outcome of human infection with leishmania (viannia) species

Journal of Infectious Diseases

Volumn 202, Issue 3, 2010, Pages 406-415

  Díaz, Yira Rosalba ^a   Rojas, Ricardo ^a   Valderrama, Liliana ^a   Saravia, Nancy Gore ^a  

^a CENTRO INTERNACIONAL DE ENTRENAMIENTO E INVESTIGACIONES MÉDICAS CIDEIM   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; GAMMA INTERFERON; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; RNA 18S; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; GATA3 PROTEIN, HUMAN; T BOX TRANSCRIPTION FACTOR; T BOX TRANSCRIPTION FACTOR TBX21; T-BOX TRANSCRIPTION FACTOR TBX21;

ADULT; AGED; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL ISOLATION; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DISEASE RESISTANCE; FEMALE; GENE EXPRESSION; HOUSEKEEPING GENE; HUMAN; LEISHMANIA; MALE; MOLECULAR CLONING; PRIORITY JOURNAL; PROMASTIGOTE; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT DISEASE; SKIN LEISHMANIASIS; TH1 CELL; TH2 CELL; ADOLESCENT; ANIMAL; BIOSYNTHESIS; COCULTURE; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGY; LEISHMANIASIS; MIDDLE AGED; MONONUCLEAR CELL; PARASITOLOGY; SECRETION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANIMALS; COCULTURE TECHNIQUES; CYTOKINES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GATA3 TRANSCRIPTION FACTOR; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; LEISHMANIA; LEISHMANIASIS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; T-BOX DOMAIN PROTEINS; TH1 CELLS; TH2 CELLS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954729554     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/653829     Document Type: Article

References (50)

1. Marsden PD. Clinical presentations of Leishmania braziliensis braziliensis. Parasitol Today 1985; 1:129-133.
2. Weigle KA, Saravia NG. Natural history, clinical evolution, and the host-parasite interaction in new world cutaneous leishmaniasis. Clin Dermatol 1996; 14:433-450.
3. Saravia NG, Weigle KA, Segura I, et al. Recurrent lesions in human Leishmania braziliensis infection: reactivation or reinfection? Lancet 1990; 336:398-402.
4. Ramírez JL, Guevara P. Persistent infections by Leishmania (Viannia) braziliensis. Mem Inst Oswaldo Cruz 1997; 92:333-338.
5. Schubach A, Marzochi MC, Cuzzi-Maya T, et al. Cutaneous scars in American tegumentary leishmaniasis patients: a site of Leishmania (Viannia) braziliensis persistence and viability eleven years after antimonial therapy and clinical cure. Am J Trop Med Hyg 1998; 58:824-827.
6. Weigle KA, Santrich C, Martinez F, Valderrama L, Saravia NG. Epidemiology of cutaneous leishmaniasis in Colombia: a longitudinal study of the natural history, prevalence, and incidence of infection and clinical manifestations. J Infect Dis 1993; 168:699-708. (Pubitemid 23254291)
7. Davies CR, Llanos-Cuentas EA, Pyke SD, Dye C. Cutaneous leishmaniasis in the Peruvian Andes: an epidemiological study of infection and immunity. Epidemiol Infect 1995; 114:297-318.
8. Muñoz G, Davies CR. Leishmania panamensis transmission in the domestic environment: the results of a prospective epidemiological survey in Santander, Colombia. Biomedica 2006; Suppl 1:131-144.
9. Saravia NG, Valderrama L, Labrada M, et al. The relationship of Leishmania braziliensis subspecies and immune response to disease expression in New World leishmaniasis. J Infect Dis 1989; 159:725.
10. Walton BC, Valverde L. Racial differences in espundia. Ann Trop Med Parasitol 1979; 73(1):23-29.
11. Llanos-Cuentas EA, Cuba CC, Barreto A, Marsden P. Clinical characteristics of human Leishmania braziliensis braziliensis infections.Trans R Soc Trop Med Hyg 1984; 78:845-846.
12. Wortmann GW, Aronson NE, Miller RS, Blazes D, Oster CN. Cutaneous leishmaniasis following local trauma: a clinical pearl. Clin Infect Dis 2000; 31:199-201.
13. Travi BL, Osorio Y, Saravia NG. The inflammatory response promotes cutaneous metastasis in hamsters infected with Leishmania (Viannia) panamensis. J Parasitol 1996; 82:454-457.
14. Bertho AL, Santiago MA, Coutinho SG. An experimental model of the production of metastases in murine cutaneous leishmaniasis. J Parasitol 1994; 80:93-99.
15. McMahon-Pratt D, Alexander J. Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or visceral disease? Immunol Rev 2004; 201:206-224.
16. Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2002; 2:845-858.
17. Convit J, Ulrico M, Fernández CT, et al. The clinical andimmunological spectrum of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1993; 87:444-448.
18. Follador I, Araú jo C, Bacellar O, et al. Epidemiologic and immunologic findings for the subclinical form of Leishmania braziliensis infection. Clin Infect Dis 2002; 34:E54-E58.
19. Melby PC, Andrade-Narvaez FJ, Darnell BJ, Valencia-Pacheco G, Tryon VV, Palomo-Cetina A. Increased proinflamatory cytokines in chronic lesions of human cutaneous leishmaniasis. Infect Immun 1994; 62:837-842.
20. Pirmez C, Yamamura M, Uyemura K, Paes-Oliveira M, Conceiccedil;ão- Silva F, Modlin RL. Cytokine patterns in the pathogenesis of human leishmaniasis. J Clin Invest 1993; 91:1390-1395.
21. Bourreau E, Prévot G, Pradinaud R, Launois P. Interleukin (IL)-13 is the predominant Th2 cytokine in localized cutaneous leishmaniasis lesions and renders specific CD4+ T cells unresponsive to IL-12. J Infect Dis 2001; 183:953-959.
22. Carvalho EM, Johnson WD, Barreto E, et al. Cell mediated immunity in American cutaneous and mucosal leishmaniasis. J Immunol 1985; 135: 4144-4148.
23. Bacellar O, Lessa H, Schriefer A, et al. Up-regulation of Th1-type responses in mucosal leishmaniasis patients. Infect Immun 2002; 70(12): 6734-6740.
24. Agnello D, Lankford CS, Bream J, et al. Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J Clin Immunol 2003; 23:147-161.
25. Messi M, Giacchetto I, Nagata K, Lanzavecchia A, Natoli G, Sallusto F. Memory and flexibility of cytokine gene expression as separable properties of human Th1 and Th2 lymphocytes. Nat Immunol 2003; 4:78-86.
26. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000; 100:655-669.
27. Zheng W, Flavell R. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997;89: 587-596.
28. Hwang ES, Szabo S, Schwartzberg P, Glimcher LH. T helper cell fate specified by kinase-mediated interaction of T-bet with GATA-3. Science 2005; 307:430-433.
29. Mantel PY, Kuipers H, Boyman O, et al. GATA-3-driven Th2 responses inhibit TGF-b1-induced FOXP3 expression and the formation of regulatory T cells. PLoS Biol 2007; 5(12):e329.
30. Lund R, Aittokallio T, Nevalainen O, Lahesmaa R. Identification of novel genes regulated by IL-12, IL-4, or TGF-b during the early polarization of CD4+ lymphocytes. J Immunol 2003; 171:5328-5336.
31. Wu CY, Kirman JR, Rotte MJ, et al. Distinct lineages of TH1 cells have differential capacities for memory cell generation in vivo. Nat Immunol 2002; 3:852-858.
32. Afkarian M, Sedy JR, Yang J, et al. T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4+ T cells. Nat Immunol 2002; 3:549-557.
33. Farrar J, Ouyang W, Löhning M, et al. An instructive component in T helper cell type 2 [Th2] development mediated by GATA-3. J Exp Med 2001; 193:643-649.
34. Bosque F, Saravia NG, Valderrama L, Milon G. Distinct innate and acquired immune responses to Leishmania in putative susceptible and resistant human populations endemically exposed to L. (Viannia) panamensis infection. Scand J Immunol 2000; 51:533-541.
35. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005; 22:329-341.
36. Zorn E, Nelson EA, Mohseni A, et al. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 2006; 108:1571-1579.
37. Popmihajlov Z, Smith KA. Negative feedback regulation of T cells via interleukin-2 and FOXP3 reciprocity. PLoS ONE 2008; 3:e1581.
38. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 2002; 420:502-507.
39. Anderson CF, Oukka M, Kuchroo VJ, Sacks D. CD4+CD25- Foxp3- Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J Exp Med 2007; 204:285-297.
40. Campanelli AP, Roselino AM, Cavassani KA, et al. CD4+CD25+ T cells in skin lesions of patients with cutaneous leishmaniasis exhibit phenotypic and functional characteristics of natural regulatory T cells. J Infect Dis 2006; 193:1313-1322.
41. Escobar MA, Saravia NG, Weigle K. Concurrent mucosal leishmaniasis and pulmonary tuberculosis: two case reports and review. Clin Infect Dis 1996; 23:836-837.
42. Löhning M, Richter A, Radbruch A. Review. Cytokine memory of T helper lymphocytes. Adv Immunol 2002; 80:115-181.
43. Lavenu-Bombled C, Trainor CD, Makeh I, Romeo PH, Max-Audit I. Interleukin-13 gene expression is regulated by GATA-3 in T cells: role of a critical association of a GATA and two GATG motifs. J Biol Chem 2002; 277:18313-18321.
44. Cáceres-Dittmar G, Tapia FJ, Sánchez MA, et al. Determination of the cytokine profile in American cutaneous leishmaniasis using the polymerase chain reaction. Clin Exp Immunol 1993; 91:500-505.
45. Skapenko A, Kalden JR, Lipsky PE, Schulze-Koops H. The IL-4 receptor a-chain-binding cytokines, IL-4 and IL-13, induce forkhead box P3- expressing CD25+CD4+ regulatory T cells from CD25-CD4+ precursors. J Immunol 2005; 175:6107-6116.
46. Chomarat P, Banchereau J. Interleukin-4 and interleukin-13: their similarities and discrepancies. Int Rev Immunol 1998; 17:1-52.
47. Minty A, Chalon P, Derocq JM, et al. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 1993; 362:248-250.
48. Nylén S, Maasho K, Söderstrom K, Ilg T, Akuffo H. Live Leishmania promastigotes can directly activate primary human natural killer cells to produce interferon-gamma. Clin Exp Immunol 2003; 131:457-467.
49. Matthews D, Emson C, McKenzie G, Jolin H, Blackwell J, McKenzie A. IL-13 is a susceptibility factor for Leishmania major infection. J Immunol 2000; 164:1458-1462.
50. Tiemessen MM, Jagger AL, Evans HG, van Herwijnen MJ, John S, Taams LS. CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci U S A 2007; 104:19446-19451.